CCI-779 in Treating Patients With Metastatic Melanoma

Phase 2 Completed City of Hope Medical Center National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CCI-779 in treating patients who have metastatic melanoma.

Timeline

Start: 2001-06
Primary completion: 2005-09
Completion: 2005-09

Outcome

Missed primary endpoint

paper CCI-779 was not sufficiently active in melanoma to warrant further testing as a single agent. PMID 16007689 ↗

Publications

Results Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, Gajewski T, Quirt I, Doroshow JH. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer. 2005 Sep 1;104(5):1045-8. doi: 10.1002/cncr.21265.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Temsirolimus	Small molecule	250 mg	Intravenous